Defactinib & Avutometinib: FRAME Trial – Solid Tumors
- The landscape of cancer research is frequently enough influenced by competing interests, especially financial ties between researchers and pharmaceutical companies.
- reports receiving honoraria for consulting and advisory roles from companies including AbbVie, AstraZeneca, and Merck Sharpe Dohme.
- has consulting or advisory roles with Bayer, Guardant Health, and Roche, among others.
Uncover how “competing interests” are shaping the cancer research landscape. News Directory 3 examines the intricate financial ties between researchers and pharmaceutical companies, revealing potential impacts on study outcomes. Our report highlights the diverse advisory roles, research grants, and travel expenses influencing key players in this field. We dissect how openness about these associations is vital for maintaining research integrity and delivering unbiased results. explore the commercial interests of the Institute for Cancer Research, and discover the key role of clarity in the scientific process. Learn about the crucial financial connections and their effect on the advancement of new therapies. What’s next for the future of medical research?
competing Interests shape Cancer Research Landscape
Updated June 27, 2025
The landscape of cancer research is frequently enough influenced by competing interests, especially financial ties between researchers and pharmaceutical companies. Several experts have disclosed various relationships that could perhaps affect their work.
S.B. reports receiving honoraria for consulting and advisory roles from companies including AbbVie, AstraZeneca, and Merck Sharpe Dohme. These honoraria and expenses cover a range of activities, from consulting to serving on advisory boards. Additionally, S.B. has received research funding from astrazeneca and GlaxoSmithKline and leads Verastem-sponsored trials.
M.G.K. has consulting or advisory roles with Bayer, Guardant Health, and Roche, among others. Speaker fees have been received from BMS, Eisai, and Janssen. Travel and accommodation expenses were covered by BerGenBio,BMS,and Zai Lab. Research grants have also been provided by Novartis and Roche.
Other researchers, including A.G., A.I.G., V.S.P., A.T., R.C., R.G., and N.T., declare no competing interests.
R.S.has received travel expenses from Bayer and AstraZeneca for educational symposia. M.R., R.R., R.G., K.S., T.P., M.P., J.R., C.Y., A.S., J.S.d.B., and U.B. are employees of the Institute for Cancer Research (ICR).S.S. has received research grants from Verastem Oncology and Merck Sharpe Dohme, along with advisory board honoraria from Ellipses Pharma and Exscientia/Recursion.J.R. has received an advisory board honorarium from Novartis.
C.Y. has received honoraria from Faron Pharmaceuticals,Bayer,Trogenix,and Merck. A.S. has received travel support from Sanofi, Roche-genentech, and Nurix, along with honoraria as a speaker from Astellas Pharma and Merck Sharp Dohme.A.P. declares no competing interests.
J.L. has received research grants from Roche-Genentech, Astex, merck Sharp Dohme, Janssen, and Verastem Oncology, and serves on the advisory boards of Basilia, Roche, GlaxoSmithKline, and Servier. A.M. has received research grants from Astex, Merck, and Merck Sharp Dohme, along with honoraria from Chugai, Faron, Merck, GlaxoSmithKline, Seagen, Takeda, and Janssen. J.S.d.B. is named as an inventor on a patent submitted by Janssen, covering the use of abiraterone acetate with corticosteroids, and has received research support from various companies.
U.B. is named as an inventor on patents arising from a trial, with the ICR having a licence agreement with Verastem oncology. U.B. is due to receive a proportion of income from this license. The Institute of Cancer research has commercial interests in CYP17,AKT,CHK1,RAF,MPS1,FLT3/Aurora Kinase inhibitors,GCN2 activators,molecular glues,and folate-targeted thymidylate synthetase inhibitors.
What’s next
Continued transparency and disclosure of competing interests remain vital to maintaining the integrity and objectivity of cancer research. Further studies and analyses will likely explore the impact of these relationships on research outcomes and clinical practices.